Edition:
United States

Concordia International Corp (CXRX.OQ)

CXRX.OQ on NASDAQ Stock Exchange Global Select Market

0.50USD
3:59pm EST
Change (% chg)

$-0.00 (-0.98%)
Prev Close
$0.50
Open
$0.50
Day's High
$0.52
Day's Low
$0.50
Volume
6,853
Avg. Vol
50,405
52-wk High
$3.52
52-wk Low
$0.45

Chart for

About

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

Drug firm Concordia overcharged Britain's health service with 6,000 percent price rise

LONDON Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

Nov 21 2017

UPDATE 1-Drug firm Concordia overcharged Britain's health service with 6,000 pct price rise

LONDON, Nov 21 Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

Nov 21 2017

Britain says Canada's Concordia overcharging health service for thyroid drug

LONDON, Nov 21 Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

Nov 21 2017

BRIEF-Concordia International ‍comments on UK CMA statement of objections related to Liothyronine

* ‍COMMENTS ON CMA STATEMENT OF OBJECTIONS RELATED TO LIOTHYRONINE; SAYS "DO NOT BELIEVE THAT COMPETITION LAW HAS BEEN INFRINGED​"

Nov 21 2017

BRIEF-Concordia International Q3 ‍reported revenue $154.6 mln

* Concordia International announces third quarter 2017 results

Nov 14 2017

BRIEF-Concordia International seeks to realign capital structure under CBCA

* Concordia International Corp. takes next step to realign its capital structure by commencing proceedings under the Canada Business Corporations Act

Oct 20 2017

BRIEF-Concordia International - ‍decided to use a 30-day grace period to defer payment of about $26 million

* Concordia International - ‍decided to use a 30-day grace period to defer payment of about $26 million of interest due oct 16 on its $735 million unsecured notes​

Oct 16 2017

BRIEF-Concordia International-‍ UK CMA investigating into co's international segment

* Concordia International-‍ UK CMA investigating issues related to UK pharmaceutical sector, co's international segment,certain products part of inquiry​

Oct 11 2017

BRIEF-Concordia International says ‍UK Competition and Markets Authority investigating pharma sector​

* Says ‍UK competition and markets authority is investigating new issues in relation to UK pharmaceutical sector​

Oct 11 2017

BRIEF-Concordia International Corp. Announces release date for deliver strategy

* Concordia International Corp. Announces release date for deliver strategy

Aug 30 2017

Earnings vs. Estimates